For the better part of its 31-year existence, the biotech industry has been about research and innovation. Thousands of prospective drugs and therapies have made the daunting and time-consuming journey from lab to clinical trial.Drugs like Herceptin, Gleevac and Rituxan, made it to the bedside of patients only after billions of dollars had been spent. But the nascent industry not only survived but also now is poised to thrive.
